Pipeline Preview as reported July 1, 2002
IQVIA: Patients Unlikely to See Savings from Medicare’s Drug Price Negotiation
The IQVIA analysis finds that the impact of drug price negotiation on patients’ out-of-pocket spending could also be smaller than expected.
Read More
FDA Accepts NDA for Menopause Drug, Elinzanetant
If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief.
Trilliant Report Finds the Money Spent on Healthcare Doesn’t Provide Value
Sanjula Jain of Trilliant Health talks about how employers are best positioned to demand value for money from the U.S. healthcare system.
UnitedHealthcare Adds Deductibles to Medicare Part D for 2025
UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.
NDA Resubmitted for Dry Eye Treatment Reproxalap
Dry eye disease affects up to 15% of the U.S. population and is one of the largest markets in the ophthalmology field.
Stelara Biosimilar Otulfi Approved by FDA to Treat Multiple Autoimmune Disorders
Otulfi is the fourth Stelara biosimilar to be approved by the FDA.
